Immunic Inc (IMUX) USD0.0001

Sell:$0.94Buy:$0.95$0.02 (2.02%)

NASDAQ:1.35%
Market closed | Prices delayed by at least 15 minutes
Sell:$0.94
Buy:$0.95
Change:$0.02 (2.02%)
Deal now
Market closed | Prices delayed by at least 15 minutes
Sell:$0.94
Buy:$0.95
Change:$0.02 (2.02%)
Market closed | Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

Immunic, Inc. is a biotechnology company. The Company is focused on developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases. The Company’s s lead development program, vidofludimus calcium (IMU-838), is in phase III and phase II clinical trials for the treatment of relapsing and progressive multiple sclerosis, respectively, and has shown therapeutic activity in phase II clinical trials in patients suffering from relapsing-remitting multiple sclerosis, progressive multiple sclerosis, and moderate-to-severe ulcerative colitis. IMU-856, which targets the protein Sirtuin 6 (SIRT6), is intended to restore intestinal barrier function and regenerate bowel epithelium, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease. IMU-381 is in preclinical testing, a next generation molecule being developed to specifically address the needs of gastrointestinal diseases.

Key people

Duane D. Nash
Executive Chairman of the Board
Jason Tardio
President, Chief Operating Officer
Daniel Vitt
Chief Executive Officer, Director
Glenn Whaley
Chief Financial Officer
Hella Kohlhof
Chief Scientific Officer
Inderpal Singh
General Counsel
Werner Gladdines
Chief Development Officer
Andreas Muehler
Chief Medical Officer
Patrick Walsh
Chief Business Officer
Barclay A. Phillips
Lead Independent Director
Simona Skerjanec
Director
Tamar D. Howson
Independent Director
Joerg Neermann
Independent Director
Richard Rudick
Independent Director
Click to see more

Key facts

  • EPIC
    -
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US4525EP1011
  • Market cap
    $86.96m
  • Employees
    77
  • Shares in issue
    90.08m
  • Exchange
    NASDAQ
  • Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.